-
1
The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative
Published 2025-02-01“…Abstract: Clinical trial design for classical hematologic diseases is difficult because samples sizes are often small and not representative of the disease population. The American Society of Hematology initiated a roadmap project to identify barriers and make progress to integrate diversity, equity, and inclusion into trial design and conduct. …”
Get full text
Article -
2
The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
Published 2024-10-01“…Ongoing trials are also outlined, including the data presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the 2024 European Hematology Association (EHA) Congress and the 21st International Myeloma Society (IMS) Annual Meeting 2024. …”
Get full text
Article -
3
RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC
Published 2024-02-01“…The initial platelet counts and bleeding symptoms were recorded, and initial and long-term responses to treatment were evaluated based on the American Society of Hematology guidelines. Results: The mean age of the patients was 42.1 years with a male-to-female ratio of 1:1.8. …”
Get full text
Article